Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2611054 | 0.83 | EGFR (0.55) | EGFRPIK3CDPIK3CAFGFR4TDO2 | |
| SCHEMBL23335615 | 0.80 | EGFR (0.51) | EGFRPIK3CDPIK3CAFGFR4TDO2 | |
| SCHEMBL27666530 | 0.80 | EGFR (0.51) | EGFRPIK3CDPIK3CAFGFR4TDO2 | |
| SCHEMBL30804805 | 0.80 | EGFR (0.55) | EGFRPIK3CDPIK3CAFGFR4TDO2 | |
| SCHEMBL2619213 | 0.79 | EGFR (0.50) | EGFRPIK3CDPIK3CAFGFR4TDO2 | |
| SCHEMBL20032418 | 0.75 | EGFR (0.50) | EGFRPIK3CDPIK3CAFGFR4TDO2 | |
| SCHEMBL20666511 | 0.74 | EGFR (0.56) | EGFRPIK3CDPIK3CAFGFR4TDO2 | |
| SCHEMBL28236647 | 0.74 | EGFR (0.45) | EGFRPIK3CDPIK3CAFGFR4TDO2 | |
| SCHEMBL28236646 | 0.74 | EGFR (0.45) | EGFRPIK3CDPIK3CAFGFR4TDO2 | |
| SCHEMBL21646348 | 0.72 | EGFR (0.68) | EGFRPIK3CDPIK3CAFGFR4TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352360-B2 | TGF-beta inhibitors | Rigel Pharmaceuticals, hic. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20200031832-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352360-B2 | TGF-beta inhibitors | TGFBR1, TGFBR2, TGFB1 | EGFR 294/4885PIK3CD 3202/4885PIK3CA 2831/4885 |
| US-20200031832-A1 | TGF-Beta Inhibitors | TGFBR1, TGFBR2, TGFB1 | EGFR 294/4885PIK3CD 3202/4885PIK3CA 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.